Cetera Investment Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.45M Buy
58,648
+2,612
+5% +$62.2K ﹤0.01% 2570
2025
Q4
$1.31M Buy
56,036
+3,557
+7% +$79.2K ﹤0.01% 2598
2025
Q3
$1.03M Sell
52,479
-2,249
-4% -$46.3K ﹤0.01% 2742
2025
Q2
$1.19M Sell
54,728
-3,452
-6% -$81.5K ﹤0.01% 2229
2025
Q1
$1.41M Buy
58,180
+15,066
+35% +$339K ﹤0.01% 1996
2024
Q4
$900K Buy
43,114
+11,221
+35% +$241K ﹤0.01% 2230
2024
Q3
$634K Sell
31,893
-2,053
-6% -$38.1K ﹤0.01% 2461
2024
Q2
$526K Buy
33,946
+5,197
+18% +$80.9K ﹤0.01% 2557
2024
Q1
$458K Buy
28,749
+6,933
+32% +$104K ﹤0.01% 2669
2023
Q4
$367K Buy
21,816
+6,533
+43% +$89.3K ﹤0.01% 1667
2023
Q3
$179K Buy
15,283
+60
+0.4% +$803 ﹤0.01% 2002
2023
Q2
$205K Buy
15,223
+1,096
+8% +$15.8K ﹤0.01% 1975
2023
Q1
$234K Buy
14,127
+1,127
+9% +$18.6K ﹤0.01% 1854
2022
Q4
$242K Buy
+13,000
New +$200K ﹤0.01% 1791
2022
Q3
Sell
-17,275
Closed -$121K 1764
2022
Q2
$121K Hold
17,275
﹤0.01% 1725
2022
Q1
$143K Sell
17,275
-377
-2% -$2.67K ﹤0.01% 1770
2021
Q4
$120K Hold
17,652
﹤0.01% 1780
2021
Q3
$94K Hold
17,652
﹤0.01% 1739
2021
Q2
$101K Buy
17,652
+543
+3% +$2.8K ﹤0.01% 1722
2021
Q1
$79K Buy
17,109
+109
+0.6% +$433 ﹤0.01% 1565
2020
Q4
$57K Buy
+17,000
New +$57.1K ﹤0.01% 1539

Other funds holding CPRX

Cetera Investment Advisers's CPRX Position: Q1 2026 in Review

Cetera Investment Advisers increased its Catalyst Pharmaceutical (CPRX) stake by 4.7% in Q1 2026, buying an estimated $62.2K and bringing the position to 58,648 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2570.

Cetera Investment Advisers first reported a position in CPRX in Q4 2020 and has held it in 21 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Cetera Investment Advisers held 58,648 shares of Catalyst Pharmaceutical worth $1.45M as of Q1 2026.
  • Cetera Investment Advisers bought 2,612 Catalyst Pharmaceutical shares in Q1 2026, an estimated $62.2K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #2570 holding.
  • Cetera Investment Advisers first reported a position in Catalyst Pharmaceutical in Q4 2020 and has held it in 21 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.